Vorinostat as a radiosensitizer for brain metastasis: A phase i clinical trial

Journal of Neuro-Oncology

Volumn 118, Issue 2, 2014, Pages 313-319

  Shi, Wenyin ^a   Lawrence, Yaacov Richard ^a,c   Choy, Hak ^b   Werner Wasik, Maria ^a   Andrews, David W ^a   Evans, James J ^a   Judy, Kevin D ^a   Farrell, Christopher J ^a   Moshel, Yaron ^a   Berger, Adam C ^a   Bar Ad, Voichita ^a   Dicker, Adam P ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Brain metastasis; Phase I; Radiosensitizer; Vorinostat; Whole brain radiation

Indexed keywords

VORINOSTAT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; RADIOSENSITIZING AGENT;

ADULT; AGED; ANOREXIA; ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; ESOPHAGITIS; FATIGUE; FEMALE; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; LUNG EMBOLISM; MALE; MIDDLE AGED; MOUTH PAIN; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIOSENSITIZATION; RASH; RECOMMENDED DRUG DOSE; SKIN ULCER; TREATMENT DURATION; VOMITING; WHOLE BRAIN RADIATION TREATMENT; BRAIN NEOPLASMS; CANCER GRADING; CHEMORADIOTHERAPY; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; KAPLAN MEIER METHOD; NON SMALL CELL LUNG CANCER; PATHOLOGY; SECONDARY; TREATMENT OUTCOME; UTERINE TUBE TUMOR;

AGED; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; COHORT STUDIES; DISEASE PROGRESSION; FALLOPIAN TUBE NEOPLASMS; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; RADIATION-SENSITIZING AGENTS; TREATMENT OUTCOME;

EID: 84903894771     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1433-2     Document Type: Article

References (43)

1. Andrews DW (2008) Current neurosurgical management of brain metastases. Semin Oncol 35:100-107
2. Auperin A et al (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 341:476-484
3. Baschnagel A et al (2009) Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther 8:1589-1595
4. Bratland A et al (2011) Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy. Radiat Oncol 6:33
5. Camphausen K et al (2005) Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 114:380-386
6. Cerna D, Camphausen K, Tofilon PJ (2006) Histone deacetylation as a target for radiosensitization. Curr Top Dev Biol 73:173-204
7. Chang JE, Robins HI, Mehta MP (2007) Therapeutic advances in the treatment of brain metastases. Clin Adv Hematol Oncol 5:54-64
8. Chinnaiyan P et al (2012) Phase i trial of vorinostat combined with bevacizumab and cpt-11 in recurrent glioblastoma. Neuro Oncol 14:93-100
9. Chinnaiyan P et al (2005) Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 62:223-229
10. Deorukhkar A et al (2010) Inhibition of radiation-induced DNA repair and prosurvival pathways contributes to vorinostat-mediated radiosensitization of pancreatic cancer cells. Pancreas 39:1277-1283
11. Duvic M et al (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, saha) for refractory cutaneous t-cell lymphoma (ctcl). Blood 109:31-39
12. Fakih MG et al (2012) A randomized phase ii study of two doses of vorinostat in combination with 5-fu/lv in patients with refractory colorectal cancer. Cancer Chemother Pharmacol 69:743-751
13. Friday BB et al (2012) Phase ii trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol 14:215-221
14. Galanis E et al (2009) Phase ii trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27:2052-2058
15. Galanis E et al (2009) Phase ii trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27:2052-2058
16. Gallinari P et al (2007) Hdacs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 17:195-211
17. Gaspar L et al (1997) Recursive partitioning analysis (rpa) of prognostic factors in three radiation therapy oncology group (rtog) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745-751
18. Hockly E et al (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of huntington's disease. Proc Natl Acad Sci USA 100:2041-2046
19. Ilker YE et al (2005) Suberoylanilide hydroxamic acid (saha) has potent anti-glioma properties in vitro, ex vivo and in vivo. J Neurochem 93:992-999
20. Karagiannis TC, El-Osta A (2006) Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene 25:3885-3893
21. Kim MS et al (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63:7291-7300
22. Kim MS et al (2001) Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7:437-443
23. Marks P et al (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev 1:194-202
24. Marks PA et al (2004) Histone deacetylase inhibitors. Adv Cancer Res 91:137-168
25. Mueller S et al (2011) Cooperation of the hdac inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett 306:223-229
26. Munshi A et al (2005) Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11:4912-4922
27. Munshi A et al (2006) Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-h2ax foci. Mol Cancer Ther 5:1967-1974
28. Palmieri D et al (2009) Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res 15:6148-6157
29. Patchell RA et al (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280:1485-1489
30. Patchell RA et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494-500
31. Peereboom DM (2012) Clinical trial design in brain metastasis: approaches for a unique patient population. Curr Oncol Rep 14:91-96
32. Ramalingam SS et al (2010) Phase i study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a national cancer institute organ dysfunction working group study. J Clin Oncol 28:4507-4512
33. Ramaswamy B et al (2012) Phase i-ii study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and hsp90 inhibition in vivo. Breast Cancer Res Treat 132:1063-1072
34. Ree AH et al (2010) Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the pelvic radiation and vorinostat (pravo) phase 1 study. Lancet Oncol 11:459-464
35. Richon VM (2006) Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer 95:S2-S6
36. Richon VM et al (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95:3003-3007
37. Schneider BJ et al (2012) Phase i study of vorinostat (suberoylanilide hydroxamic acid, nsc 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Invest New Drugs 30:249-257
38. Sperduto PW et al (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the rtog database. Int J Radiat Oncol Biol Phys 70:510-514
39. Stathis A et al (2011) Phase i study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-hodgkin's lymphomas. Clin Cancer Res 17:1582-1590
40. Suh JH (2010) Stereotactic radiosurgery for the management of brain metastases. N Engl J Med 362:1119-1127
41. Ugur HC et al (2007) Continuous intracranial administration of suberoylanilide hydroxamic acid (saha) inhibits tumor growth in an orthotopic glioma model. J Neurooncol 83:267-275
42. Yin D et al (2007) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 13:1045-1052
43. Zhang Y, Jung M, Dritschilo A (2004) Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 161:667-674